Clinical Trial Update: Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial exploring sirolimus combined with docetaxel and carboplatin in metastatic castration-resistant prostate cancer; the study status is terminated w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• DOCETAXEL (DOCETAXEL)
• Sirolimus (Sirolimus)

Snippet

Sponsor: University of Washington | Conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-10-01